Prospective Trial on the Pharmacokinetics of Clopidogrel in Hemodialysis Patients

Introduction: Hemodialysis patients (HDPs) exhibit extensive cardiovascular risk. The widely prescribed anti-platelet agent clopidogrel is metabolically activated by cytochrome enzymes, which may be impaired by uremia and chronic low-grade inflammation, typically present in HDPs. We conducted a pros...

Descripció completa

Dades bibliogràfiques

Autors principals:	Juergen Grafeneder, Wisse van Os, Iris K. Minichmayr, Katarina D. Kovacevic Miljevic, Birgit Reiter, Marcus D. Säemann, Veronika Machold-Fabrizii, Amro Ahmed, Paul Spechtl, Haris Omic, Raute Sunder-Plaßmann, Bernd Jilma, Christian Schoergenhofer, Farsad Eskandary
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-10-01
Col·lecció:	Kidney International Reports
Matèries:	cardiovascular risk clopidogrel cytochrome P450 hemodialysis pharmacokinetics platelet aggregation
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S246802492401859X
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!